Pulmatrix (NASDAQ:PULM) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a report published on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Pulmatrix Price Performance

Shares of PULM opened at $6.86 on Friday. The company has a market cap of $25.05 million, a PE ratio of -2.60 and a beta of 1.54. The firm has a 50-day moving average of $4.69 and a 200-day moving average of $2.99. Pulmatrix has a one year low of $1.55 and a one year high of $8.44.

About Pulmatrix

(Get Free Report)

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.

See Also

• Five stocks we like better than Pulmatrix
• What Are Dividend Achievers? An Introduction
• 3 Must-Hold Stocks with Double-Digit Upside for 2025
• Insider Trading – What You Need to Know
• Micron: Why Now Is the Time to Be Brave
• Investing in Construction Stocks
• 3 Stocks That Wall Street Insiders Can’t Stop Buying